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1. Introduction
The nosography of pancreatitis has been modified because the established distinction between
acute and chronic pancreatitis is under critical revision. In this argument there is a reduced
availability or absence of histological data connected to a clinical picture; on the other hand
the various classifications are based exclusively on clinical or laboratory data or on imaging
exams [1]. Moreover, the extremely diversified territorial distribution of the various forms of
pancreatitis generates uncertainties: this often provides different experiences to different
observers. The rigorous distinction between acute and chronic pancreatitis has represented
the basis of classifications in which there have been two distinct diseases. More recently, more
comprehensive, prolonged and detailed clinical observations have enabled a more thorough
knowledge of pancreatitis. These observations show that acute and chronic pancreatitis
overlap [1]. According to these new perspectives, two clinical pictures should be reviewed and
reconsidered: the onset and/or the acute manifestations of chronic pancreatitis due to severe
tissue inflammation more evident than main/branch duct dilation; and acute pancreatitis that
evolves anatomo-clinically towards chronic forms, because of the recurrence of acute episodes
with evolution of inflammation in fibrosis, sclerosis and calcifications. The aim of the chapter
is to evaluate surgical procedures with a minimally invasive approach as the preferred choice,
demonstrating separately the diagnostic and therapeutic pathways for acute and chronic
pancreatitis.
2. Acute pancreatitis
Acute pancreatitis is one of the most common gastrointestinal diseases. An increase in the
annual incidence for acute pancreatitis has been reported in many countries. In the United
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States, pancreatitis is among the most common gastrointestinal diseases requiring acute
hospitalization [2,3]. The incidence of acute pancreatitis varies between 4.8 to 24.2 cases per
population of 100,000 following data from England, Denmark and theUS, but has been also
associated with an incidence of 40-50 cases per 100,000 habitants a year [4]. While part of this
increase is certainly due to better clinical and diagnostic knowledge of these diseases, the
possibility of a real increase cannot be ruled out [5]. Acute pancreatitis is a complex gastroin‐
testinal disease with various aetiologies, most frequent biliary and alcoholic. Clinical presen‐
tation shows different degrees of severity with biphasic evolution. Acute pancreatitis is an
inflammatory disease that can occur in an oedematous reversible form, most frequently, or in
a necrotic one that is less frequent. Inflammatory diseases of the pancreas are characterized by
autodigestion processes of the gland carried out by enzymes that have been inappropriately
activated in the gland. Activation of trypsinogen into trypsin within the acinar cells is the
starting event. The activation of other pancreatic proenzymes follows (proelastase, chymo‐
trypsinogen, etc.). This autoactivation process of trypsin leads to pancreatic acinar cell damage
with spillage of activated enzymes into the pancreatic and peripancreatic tissue [6-8].
2.1. Aetiological and nosographic assessment as a guide for surgery in therapeutic
programmes
Many factors play an aetiological role in acute pancreatitis. In most countries biliary lithiasis
and excessive alcohol consumption are the most frequent causes reaching a total incidence of
80%. Moreover, numerous other causes of pancreatitis are recognized that represent 20% of
the total [9]. This remaining 20% constitutes a rather various group of causes of pancreatitis:
hypercalcaemia, hypertriglyceridaemia, hereditary causes, sphincter of Oddi dysfunction,
pancreas divisum, pancreatic neoplasms, medications, infections and parasitic agents,
endoscopic retrograde cholangiopancreatography (ERCP) trauma (table. 1).
Common causes Uncommon causes Rare causes
Gallstones
Alcoholism
Hypertriglyceridaemia
Post–endoscopic retrograde
cholangiopancreatography
Drug use
Autoimmunity
Genetics
Abdominal trauma
Postoperative causes
Sphincter of Oddi dysfunction
Ischaemia
Infections
Hypercalcaemiaand
hyperparathyroidism
Pancreas divisum
Annular pancreas
Scorpion venom
Posterior penetrating ulcer
Table 1. Aetiology of acute pancreatitis
Therefore pancreatitis can be considered diseases with different aetiological incidences in
different countries based on environmental features and lifestyle.
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In the current  clinical  appearance of  acute pancreatitis  the majority of  patients  (70-80%)
present with a mild-moderate disease; however, approximately 20-30% run a severe course
and require  appropriate  management  in  an  intensive  care  unit.  In  the  severe  forms,  in
approximately  20% of  cases,  development  of  persistent  organ failure  and/or  of  infected
pancreatic complications necessitates the definition of the most severe forms, identified as
critical, early severe acute pancreatitis [10,11]. Critical forms are characterized by a short
course,  progressive  multiple  organ  dysfunction,  early  hypoxaemia,  high  computed
tomography  severity  index  (CTSI),  and  increased  incidences  of  necrosis,  infection  and
abdominal compartment syndrome (ACS). Early severe acute pancreatitis mortality rate can
be very high: 40% according to the literature. [12-16]
Severe acute pancreatitis can be seen as a biphasic disease, with the first two weeks phase
characterized by early toxic-enzymatic injury (systemic inflammation response syndrome
(SIRS)) and a late phase—in the third and fourth week—characterized by septic complications
(infection of necrotic tissue and of peripancreatic fluid collection). Pancreatitis can present
different severities in the first (toxic) phase: it can be self-limiting or quickly responsive to
intensive care (especially rehydration), or it can quickly evolve into SIRS and multi-organ
failure (MOF). The acute pancreatitis may progress and worsen from local disease to general
involvement. The key of this evolution is the tissue response of the pancreas to acinous cell
necrosis. Local actions of phlogosis lead to the activation of local macrophages and attraction
of activated polymorphonuclear cells. General diffusion of phlogosis (SIRS) can develop from
the passage of inflammatory mediators (pro-anti inflammatory mediators released from the
splanchnic area) to systemic compartments by the lymphatic system, portal veins, and general
circulation. Vascular alterations cause gut barrier failure with translocation by bacteria and
endotoxin diffusion. The final results are distant organfailure (MOF) and generally later
infection of fluid-necrotic pancreatic-peripancreatic gatherings [17-25].
The examination and evaluation of homogeneous clinical cases allows us to clarify the surgical
options in the overall treatment programme. In our institution between 1998 to 2013 we
observed and treated 304 pancreatitis cases, 294 acute biliary pancreatitis cases, and ten chronic
alcoholic pancreatitis cases. The mean age was 49 years (range 30-86 years). Male:female ratio
was 1:1.33 (table 2).
304 pancreatitis-mean age 49 yrs. (range 30-86 yrs.)- M:F ratio 1:1.33
Acute pancreatitis Chronic pancreatitis
294 10
Table 2. Demographic data, 304 pancreatitis.
An acute episode of pancreatitis was defined, at first assessment, on the basis of the clinical
appearance of nausea, vomiting and abdominal pain in mesogastrium radiating through the
back with abdominal wall tenderness (superficial/depth) and muscular rigidity of varying
degrees, and laboratory data with almost twice the normal increase of the serum lipase and
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pancreatic amylase. This initial diagnostic phase was completed by evaluation of the involve‐
ment of general conditions and of the degree of pancreatic impairment by abdominal US.
Biliary aetiology was confirmed in 294 patients. This group included 93 patients with previous
repeated episodes (31.63%). Among the 93 recurrent pancreatitis cases were also 20 patients,
recently observed, with recurrent unexplained pancreatitis at first aetiological evaluation [26].
The biliary aetiology of pancreatitis has been established in a large majority of patients at initial
etiological assessment by the research on abdominal US, gallbladder lithiasis, and/or gall‐
stones, sludge, microlithiasis, etc. in the common bile duct (CBD), or also a dilation of the CBD
(>8mm) with the addition of liver function tests, fasting serum calcium, and lipid profile (Tab
3). In 20% of these patients alcohol consumption slightly over the average has also been noted.
Twenty patients (6.8%) have been diagnosed with recurrent unexplained forms at first-level
aetiological assessment. The following diagnostic study, MRCP and/or endoscopic US,
confirmed the biliary origin of pancreatitis in the majority of cases (14 patients). Only in six
cases did the aetiology of pancreatitis remain unexplained. Following empirical criteria, four
cholecystectomies and two ERCP/ES procedures were carried out in these six patients whose
aetiology remained undefined and who had already undergone cholecystectomy.
Dir Bil
(0.02-0.30 mg/dL)
<2 mg/dl
Dir Bil
(0.02-0.30 mg/dL)
2 -5 mg/dl
AST/ALT X3 g-GT (7-38 u/L)>200 u/L
61.2% 38.8% 29.4% 63.4%
Serum calcium
(8.4-10.5 mg/dL)
>10.5 mg/dL
Triglyceridaemia
(40-170 mg/dL)
>170 mg/dL
Cholecystic lithiasis/
sludge
CBD size (US)
(8mm)
Undefined
aetiology
16% 43% 84% 41.3% 6.8%
Table 3. 294 acute biliary pancreatitis: percentage incidence of biliary lithiasis and cholestasis indexes at first level
aetiological assessment
Acute pancreatitis shows a wide range of disease, ranging from a mild form to a severe or early
severe, rapidly progressive illness. The most common cause of acute pancreatitis is biliary
lithiasis—almost the total number of cases in our experience. The majority of our patients had
a mild-moderate disease. Mild acute pancreatitis takes a self-limiting form characterized by
pancreatic or peripancreatic oedema and normal enhancement of pancreatic parenchyma on
contrast-enhanced CT. Moderate pancreatitis develops early acute fluid collections located in
or near the pancreas without a wall of fibrous tissue, almost always with spontaneous
regression. These forms are not accompanied by impairment of the patient’s general condition.
In summary, regarding a first-line therapeutic approach, mild-moderate acute pancreatitis
requires only supportive therapy and generally evolves towards a spontaneous recovery.
Among 294 acute biliary pancreatitis cases we have observed and treated 167 (56.80%) mild-
moderate forms, 61 (20.74%) moderate severe forms, 51 (17.34%) severe acute pancreatitis
cases, and 15 (5.10%) early severe acute pancreatitis cases. Moderate-severe acute pancreatitis
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is characterized by large, broad peripancreatic and pancreatic involvement with fluid/necrotic
collections but without impairment of general clinical conditions. Organ failure is transient or
absent. Severe forms have diffuse or local areas of non-viable pancreatic parenchyma,
peripancreatic fat necrosis, non-enhanced pancreatic parenchyma on contrast CT, and/or fluid-
necrotic peripancreatic collections with persistent or transient organ failure [27-28]. Within the
severe forms there are also critical or early severe forms with persistent or transient organ
failure and infected pancreatic and peripancreatic collections. In our patients (294) we have
applied CTSI with Balthazar scoring for the grading of acute pancreatitis and points for
necrosis [29-31]. This classification is based on morphological and functional features: local or
diffuse enlargement of the pancreas, pancreatic gland abnormalities, peripancreatic inflam‐
mation with pancreatic and peripancreatic fluid collections, and areas of non-enhanced
parenchyma. In this morphologic assessment moderate (167), moderate-severe (61), severe (51)
and early severe acute pancreatitis (15) cases have been included (table 4).
Grade B1 160 (54.42%)
Grade C2 68 (23.12%)
Grade D3 51 (17.34%)
Grade E4 15 (5.10%)
Pancreatic necrosis
0 None 228
2 Less than/equal to 30% 49
4 >30-50% 17
6 >50% -
Table 4. 294 acute biliary pancreatitis. CT severity index: CT grade point+point for necrosis (Balthazar)
The therapeutic approach of acute biliary pancreatitis usually develops in two phases follow‐
ing the evolution of the disease. The first phase in mild-moderate forms consists of simple fluid
rehydration and control of abdominal pain. In severe acute pancreatitis the first phase is
conventionally referred to the first two weeks from onset, and the initial approach is based on
intensive care, initial aggressive fluid resuscitation, low dose steroids, anticoagulatory agents
for anti-inflammatory properties, correction of hypoxaemia, enteral nutrition to preserve the
intestinal wall integrity and antibiotic prophylaxis [32]. In this phase the most important
purpose is to control and treat—by intensive care support—the impairment of the general
conditions and single or multiple organ failure that can occur. Besides, the central key in the
global therapeutic programme for acute biliary pancreatitis is the control and treatment of
papillary patency. ERCP and endoscopic sphincterotomy (ES) can assure papillary flow and
CBD cleaning if lithiasis obstacle, sludge, and microlithiasis are present. We scheduled ERCP/
ES for within three to four days from onset in 217 patients (73.8%); three patients needed to be
excluded because the procedure was not feasible. This therapeutic programme was performed
in the following cases: 64 patients with severe and early severe acute pancreatitis, 60 with
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moderate-severe disease and 73 with recurrent pancreatitis, and finally in 17 with moderate
pancreatitis. In these patients we achieved laboratoristic or US or MRCP confirmation of a
papillary or CBD lithiasic obstacle. In seven patients with severe acute and moderate-severe
pancreatitis ERCP/ES was delayed for ten days. Among 214 patients who underwent
ERCP/ES, CBD cleaning was confirmed in 163 (76.16%). The therapeutic programme of acute
biliary pancreatitis ends with videolaparocholecystectomy (VLC). The timing of the VLC is
connected with the evolution of acute pancreatitis, waiting for the stabilization of the local
phlogistic process, and of the general condition. In any case, in our opinion, the cholecystec‐
tomy should be performed in the same hospital stay [33,34]. The severe and early severe forms
of acute biliary pancreatitis were evident for local and/or systemic complications. The degree
of pancreas impairment with Balthazar score was five in severe acute pancreatitis (SAP), and
eight in early severe acute pancreatitis (ESAP). Abdominal compartment syndrome (ACS) was
demonstrated in only one patient with ESAP (1/15–6.6%), multiple organ dysfunction syn‐
drome (MODS) in six patients with ESAP (6/15–40.46%), simple organ dysfunction in 26
patients with SAP (26/51–50.98%) versus eight patients with ESAP (8/15–53.33%), pancreatic
sepsis in four patients with SAP (4/51-7.84%) versus three patients with ESAP (3/15-20%),
hypoxaemia in 34 patients with SAP (34/51-66.66%) versus 11 patients with ESAP (11/15–
73.33%). Mortality rate was 3.92% (2/51) (late) in SAP versus 13.33% in ESAP (2/15) (early).
Mortality occurred early in patients with ACS (fifth postoperative day) and in patients with
multiple organ dysfunction syndrome (first week from onset), and later in two patients who
had not undergone surgical treatment, for prolonged organ dysfunction (third and fourth
week) (table5).
SAP ESAP
Impairment degree of pancreas
(Balthazar CT score) 5 8
Abdominal compartment syndrome
(ACS) (%) - 6.6% (1/15)
Multiple organ dysfunction syndrome - 40.46% (6/15)
Simple organ dysfunction 50.98% (26/51) 53.33% (8/15)
Pancreatic sepsis 7.84% (4/51) 20% (3/15)
Hypoxaemia 66.66% (34/51) 73.33% (11/15)
Mortality 3.92% (2/51) late 13.33% (2/15) early
Table 5. Comparison of the clinical appearance of early severe acute pancreatitis (ESAP) and severe acute pancreatitis
(SAP)
These forms required appropriate management in intensive care. In early severe forms there
was a great compromise of general conditions by early toxic-enzymatic injury and high rate
of early mortality (13.33%). The later phase of the disease (third and fourth week) was
characterized by septic complications of pancreatic or peripancreatic fluid-necrotic collections.
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The preferred approach to fluid and necrotic collections was US/CT guided percutaneous
drainage. In our experience, considering 66 patients (51 SAP and 15 ESAP), we intervened only
in eight patients: three US/CT guided percutaneous drainages of peripancreatic septic
gatherings, two US/CT guided percutaneous drainages of fluid intrahepatic gatherings, and
two US/CT guided percutaneous drainages of necrotic gatherings. These minimally invasive
approaches were followed by clinical improvement without further intervention. We per‐
formed an open approach for decompression with midline laparotomy and immediate skin
coverage in one patient with ACS. In the case of late evolution of acute pancreatitis we
performed two pseudocyst-jejunostomies by an open procedure for acute postnecrotic
pseudocysts.
Complications of ERCP/ES, including post-procedural pancreatitis, perforations, bleeding and
infections are not unusual. The incidence of overall complications is evaluated to be about 10%,
with a major morbidity of 1.5% and mortality less than 0.5% [35,36]. Recent data from the
literature have shown an overall complication rate that is never negligible, but the majority of
events are of mild-to-moderate severity [37]. In our experience, we registered two duodenal
perforations (2/214-0.93%). One patient was treated with conservative therapy, and the other
case was submitted to surgical intervention by cholecystectomy, duodenostomy and gastro‐
jejunal anastomosis. Severe post-procedural pancreatitis occurred in three patients
(3/214-1.40%) and was treated with medical therapy followed by resolution with a prolonged
hospital stay (ten days). We also observed two post-ERCP bleeding cases (2/214-0.93%) treated
with an endoscopic approach (adrenalin infiltration). Minor complications such as mild
pancreatitis with hyperamylasaemia alone and rapid self-limiting evolution were observed in
18 patients (18/214–8.41%). In this endoscopic procedure it is important to identify the risk
factors in order to lower complication rates: physiopathological conditions such as Oddi
sphincter dysfunction and biliary duct dilation, technical difficulties of the manoeuvres
performed such as the use of a guide-wires, necessity to perform a pre-cut, and finally elderly
high-risk patients.
A clinical and instrumental follow-up programme, three and six months after discharge, based
on clinical control, laboratory tests and abdominal US has been planned for 294 patients with
acute biliary pancreatitis. The follow-up programme has divided the patients of ERCP/ES
(214/217 scheduled) from the patients not submitted to this therapeutic procedure (80), with
mild-moderate forms of pancreatitis. Delayed control was carried out for 124 patients
(124/214-57.94%) of the first group (submitted to ERCP/ES); 90 patients could not be reached.
The results of the follow-up, at three and six months, showed the absence of critical episodes,
and stable normalization of laboratory and instrumental cholestasis tests (table 6)
Four patients (4/124-3.22%) had a recurrence of a mild-moderate pancreatitis before the first
control. The persistence of the papillary obstacle for incomplete sphincterotomywas assessed:
the new sphincterotomy and medical therapy for resolution was performed. The same check
was performed in 38 patients with mild-moderate pancreatitis not submitted to ERCP/ES
(38/80-47.50%); 42 patients could not be reached. This control at three and six months from the
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discharge was normal. No patient had a relapse of the acute attack and the haematochemical
values of cholestasis indexes and pancreatic enzymes were normal (table 7)
Direct bilirubin (range 0,1-0,3 mg/dL) 0.21 mg/dL
Gamma-GT (range 31-64 iU/L) 48 iU/L
AST (range 22-57 iU/L) 24 iU/L
ALT (range 25-64 iU/L) 29 iU/L
Lipasaemia (range 120-221 iU/L) 171 iU/L
Pancreatic amylasaemia (range 34-72 iU/L) 42 iU/L
Alkaline phosphatase (range 67-220 iU/L) 105 iU/L
CBD size (range 5-8 mm, Abdominal US) 5 mm
Detection of CBD stones (Abdominal US) -
Table 7. 38 patients with acute biliary pancreatitis not submitted to ERCP/ES. Follow-up at three to six months (mean
of two controls)
2.2. Role of surgery in the treatment of acute pancreatitis
General guidelines for surgical treatment can be found for acute pancreatitis, mainly with
biliary pathogenesis,,which are clearly geared towards less aggression and minimally invasive
approaches.
In mild-moderate acute biliary pancreatitis the minimally invasive therapeutic approach is
the rule. The management programme includes the first-line diagnostic evaluation with the
control  of  cholestasis  laboratory tests  and of  CBD imaging (size,  lithiasis,  microlithiasis,
sludge)  by  non-invasive  instrumental  exams  (US).  Usually  the  mild-moderate  form
undergoes a favourable self-limiting evolution; in fact, it needs only supportive therapy. In
Direct bilirubin (range 0,1-0,3 mg/dL) 0.17 mg/dL
Gamma-GT (range 31-64 iU/L) 52 iU/L
AST (range 22-57 iU/L) 25 iU/L
ALT (range 25-64 iU/L) 31 iU/L
Lipasaemia (range 120-221 iU/L) 165 iU/L
Pancreatic amylasaemia (range 34-72 iU/L) 47 iU/L
Alkaline phosphatase (range 67-220 iU/L) 115 iU/L
CBD size (range 5-8 mm, Abdominal US) 7 mm
Detection of CBD stones (Abdominal US) -
Table 6. 124 patients with acute biliary pancreatitis submitted to ERCP/ES. Follow-up at three to six months (mean of
two controls)
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some patients the onset of moderate pancreatitis can be more aggressive but not with heavy
impairment of general conditions. In these cases it is useful to direct intensive care with
rehydration, control of abdominal pain, antibiotic prophylaxis, and enteral nutrition [38,39].
In patients with cholestasis index increases and/or dilation of the CBD, the MRCP should
be mandatory.  In patients  with mild-moderate forms,  without  an increase of  cholestasis
indexes, and in the absence of a dilation of the intra-and extrahepatic biliary ducts, it is all
the same useful to know if obstacles not clinically manifest are present in the CBD, and
these patients should be submitted to an MRCP before cholecystectomy. In all these cases
the extensive use of MRCP can be useful for a significant reduction in the number of non-
therapeutic ERCP/ES incidences [40,41].
Therefore if a papillary or CBD lithiasic obstacle is demonstrated, the therapeutic programme
includes assuring papillary patency and common bile duct cleaning with ERCP/ES [42-52]. In
all patients with pancreatitis with biliary pathogenesis, submitted to ERCP/ES or not, it is
necessary to perform laparoscopic cholecystectomy in the same hospital stay to complete the
gallstone treatment. The timing of laparoscopic cholecystectomy is connected with acute
pancreatitis evolution because it is preferable to wait for the stabilization and improvement of
the general condition and of the phlogistic impairment of pancreatic and peripancreatic tissue.
In severe and early severe acute biliary pancreatitis the therapeutic minimally invasive
approach is generally the procedure of choice. Severe and early severe acute pancreatitis can
develop through an altered balance between the proinflammatory reaction to pancreatic
necrosis in the peritoneal compartment (positive effect) and systemic circulation and diffusion
of the high level of anti-inflammatory mediators (negative effect). This balance alteration can
cause SIRS and MODS. The minimally invasive therapeutic programme of severe and early
severe pancreatitis follows the biphasic development of the disease. The minimal invasiveness
is necessary in the first phase because it promotes the control of the impairment of general
conditions by means of systemic intensive therapies that encompass initial aggressive fluid
resuscitation and support of vasopression (dopamine, vasopressin, etc.) [53]. In biliary severe
acute pancreatitis, the papillary obstacle (lithiasis, microlithiasis, oddities) and choledocholi‐
thiasis can have a minimally invasive endolaparoscopic approach by ERCP/ES. In the later
evolution (second phase), local complications, if not solved spontaneously, allow an efficacious
minimally invasive approach to be preferred in patients in unstable conditions. Control and
treatment of pancreatic peripancreatic gatherings (necrotic, fluid, infected) and control and
treatment of belated acute postnecrotic pseudocysts should be planned.
In the very wide perspective of the role of the surgery in the treatment of acute pancreatitis,
there are some points of discussion about the surgical therapeutic approach in various clinical
appearances, difference for timing of presentation (early-late), and degree of severity.
The indications of emergency surgical procedures for severe and early severe acute pancreatitis
are evident. This initial clinical event is placed at the onset of acute pancreatitis definitely comes
outside of septic complications, which are on the contrary characteristics of the next evolution
of the disease. In the first phase of severe acute pancreatitis the clinical scenario is dominated
by the impairment of general conditions (toxic phase), emergency surgery has restricted
indications such as ACS, and there exists cases of uncertainty of diagnosis that may persist
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even after imaging exams (US and/or CT). Aggressive fluid therapy is the rational treatment
in the early phase of severe acute pancreatitis. This treatment allows the correction of hypo‐
volaemia by third space fluid loss and a reduction of the high haematocrit that can serve as a
marker of haemoconcentration, which is present in up to 60% of patients who develop organ
failure. Aggressive fluid resuscitation with associated leaking capillaries can increase tissue
oedema with concause intra-abdominal hypertension (IAH) and ACS [54,55]. Therefore, severe
pancreatitis fluid resuscitation and capillary leakage can lead to intra-abdominal hypertension.
For this reason monitoring of intra-abdominal pressure (IAP) is necessary for patients at risk
of developing ACS. If IAP reaches 12 mmHg conservative methods such as appropriate
restriction of intravenous fluids, gastrointestinal decompression by nasogastric tube, and
drainage of ascites fluid should be applied to prevent the development of ACS. This conser‐
vative management can be successful. If ACS develops in spite of these procedures, surgical
emergency decompression should be performed. The surgical procedures used in the treat‐
ment of ACS are very complex; they can be grouped under the definition of surgical decom‐
pression. The most commonly employed surgical procedure is the midline laparotomy. All the
layers of the abdominal wall are divided by a xiphopubic vertical incision and complete
exposition of the abdominal cavity. A similar result can be achieved with a transverse bilat‐
erally extended incision few centimetres below the costal margins [56-57]. A reduction of IAP
can be achieved with both techniques. The clinical scenarios of the management of the open
abdomen are very difficult. The various methods to cover the abdominal viscera for the
necessary time until ACS improvement—generally some days—include a plastic silo (Bogotà
bag), vacuum-assisted wound closure, or a vacuum pack or self-made negative pressure
dressing. Finally vacuum-assisted wound closure combined with a mesh-mediated fascial
traction [58] has been proposed. After surgical decompression and ACS has been treated, the
following step is the abdominal wall closure. The available techniques encompass the primary
fascial closure or planned hernia with skin coverage and subsequent delayed abdominal wall
reconstruction.
In our experience, urgent surgical decompression with midline laparotomy and immediate
skin coverage has been useful in patients who have developed ACS. The uncertainty of the
diagnosis in SAP is rather unusual because of the diagnostic efficiency of laboratory and
instrumental exams. Furthermore in doubt of the acute abdomen the emergency laparotomy
is mandatory. Outside of these aforementioned clinical situations, surgical procedures should
be avoided in patients with severe pancreatitis due to the high death rate when performed
within the first few days of onset.
Patient choice and the timing of ERCP/ES are a much-debated issue in the therapy of acute
biliary pancreatitis. Papillary obstruction is widely recognized as the pathogenic factor of acute
biliary pancreatitis. The role of papillary obstruction by stones, sludge, and microlithiasis
migration to the CBD from the gallbladder with bile reflux into pancreatic ducts, was described
by Opie in 1901 [59]. It must also be remembered that the obstacle can be transitory, with the
spontaneous migration of the stones in the duodenum; in addition the transit of the stones
may be followed by inflammation and papillary sclerosis. The diagnostic confirmation of acute
biliary pancreatitis is almost always possible on the basis of clinical, laboratory and instru‐
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mental data. The severity of the disease can also be established by multifactorial scores (Ranson
[60], Glasgow [61], Apache II [62]) at the point of admission and in the first 24-48 hours, by
unifactorial markers (PCR, TAP [63], Procalcitonin [64], Hct), and subsequently by means of
imaging (Balthazar score and CTSI). In severe or early severe acute pancreatitis the initial
therapeutic approach, as mentioned, is based on aggressive fluid resuscitation, invasive
hemodynamic monitoring, intensive care, correction of hypoxaemia, and enteral nutrition [65].
Next, the cornerstone of the therapeutic programme required, in the opinion of many authors
[38-48], an urgent ERCP with endoscopic sphincterotomy. This is also in the absence of
cholangitis and sometimes without the verification of cholestasis, because the papillary
obstacle is the cause of pancreatitis. Recent evidences suggest that can useful to modify this
therapeutic choice; ERCP/ES should be performed based on clinical-laboratory evidence of
cholestasis and/or cholangitis or on demonstration of biliary or papillary obstacle by MRCP
[38,49,66,67]. Furthermore, in the course of mild-moderate acute biliary pancreatitis the ERCP/
ES is reserved for cases with a documented papillary obstacle based on the increase of
cholestasis indexes and/or of CBD size, or with obstacle presence (stones, odditis, etc.) in the
CBD demonstrated by US/MRCP. On the other hand, only the therapeutic role of ERCP/ES has
been established, while the diagnostic role for detection of CBD/papillary obstacles is played
by MRCP.
There is a difficult decision to be made about the indication of ERCP/ES in a patient with acute
pancreatitis with deterioration of general condition. Emergency ERCP in a patient submitted
to intensive care, with the requirement of assisted ventilation, is a procedure with risk. In this
clinical situation the therapeutic choice is not unanimously defined. In practice urgent ERCP/
ES (within three to four days from the onset) should be performed in severe and early severe
acute pancreatitis with cholangitis, or cholestasis or jaundice with evidence of SIRS. In
conclusion, there is no clear-cut answer to the question as to whether or not early ERCP/ES in
cases of acute biliary pancreatitis (within 24-72 hours from onset) reduces the risk of progres‐
sion of acute pancreatitis to severe disease (organ failure and/or necrosis). [38]
It is, however, determined in severe and early severe cases without evidence of cholestasis, in
recurrent acute pancreatitis, in moderate-severe pancreatitis and in patients with mild-
moderate forms, to be appropriate and useful to confirm papillary or CBD lithiasis obstacle by
laboratory, US or MRCP before therapeutic ERCP/ES. In patients with mild-moderate pan‐
creatitis without instrumental, clinical-laboratory demonstration of papillary-CBD obstruc‐
tion, the ES is not indicated. This therapeutic choice is based on the consideration that in mild-
moderate forms the papillary obstacle (without cholestasis) may be transient and the treatment
is not required [49,51].
A flow-chart of ERCP/ES employment in acute biliary pancreatitis is shown in figure 1.
The management of acute severe necrotizing pancreatitis has been much modified over time.
The prevalence of acute necrotizing pancreatitis is 15-20% and its pathological basis is the
hypoperfusion of the parenchyma on a contrast-enhanced CT (Balthazar score) [31]. The
necrotic process involves the pancreatic gland and the peripancreatic tissues with very variable
extension. The extensive interstitial oedema is associated with pancreatic and peripancreatic
necrosis in a short period of 48-72 hours after the onset of acute attack. These inflammatory,
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necrotic tissues subsequently cause acute fluid collections with an amount of devitalized tissue.
The further evolution of these fluid gatherings is characterized by demarcation between viable
and necrotic tissue, and the limit is set with a wall of granulation tissue. The management of
these pancreatic peripancreatic fluid-necrotic collections and their complications is the longest
and most debated therapeutic problem.
Particularly in question are some specific surgical decisions: how long the control and
observation of uncomplicated fluid-necrotic gatherings may be prolonged; which clinical,
laboratory and instrumental data we must follow to differentiate between infected and sterile
pancreatic necrosis; whether the intervention may be delayed for a few (four to eight) weeks
in some patients with infected necrosis when the gathering has become walled off; and finally
the choice of the best surgical approach for the treatment of fluid-necrotic complicated
collections.
In severe acute pancreatitis (necrotizing) we can distinguish between two phases in the
evolution of the disease, as is already reported; however, these two distinct phases can also be
considered in relation to the surgical procedures. There is an early toxic phase (one to two
weeks from the onset), characterized by the severe involvement of general conditions and the
start of the dreaded SIRS: in this phase the main purpose is minimizing the mortality from
MODS, and all surgical procedures should be avoided. The late phase (from the third week)
Figure 1. Flow-chart: ERCP/ES in acute biliary pancreatitis
Acute and Chronic Pancreatitis132
is characterized by the fluid-necrotic collections with or without septic complications, such as
infected pancreatic necrosis.
Uncomplicated fluid necrotic gatherings may be submitted to conservative procedures that
can be extended for four to eight weeks, when persisting peripancreatic fluid collections are
referred to as acute postnecrotic pseudocysts. If these gatherings in this phase are not symp‐
tomatic, surgical manoeuvres and percutaneous drainages should be avoided. Placement of a
drain into a sterile necrotic collection can result in secondary infection, and prolonged drainage
may increase the risk further [68,69]. Most patients with sterile necrosis show results with
conservative non-surgical management. It is debatable as to which patients the surgical
procedure to treat sterile pancreatic necrosis can be useful for. In the data from the literature
there is no complete solution, but there is a suggestion that, in selected cases with persistent
organ failure and severe impairment of general conditions despite intensive care unit therapy,
surgery may be useful in sterile necrosis [70-72]. In our experience we have undergone US/CT
guided percutaneous drainage in two patients with symptomatic fluid intrahepatic gatherings.
After diagnosis of pancreatic necrotic collections the next step is the differentiation between
sterile and infected necrosis. This diagnostic data may be essential for the therapeutic choice.
The exam of choice is the fine-needle aspiration for bacteriology (FNAB), which can usually
be guided by CT and/or US. The suspicious of infection may be based on the demonstration
by CECT of gas bubbles into the gatherings. Moreover, this should be performed in patients
with evident pancreatic peripancreatic necrotic gatherings and clinical signs of sepsis. This
diagnostic procedure is accurate and safe with a very low incidence of complications such as
bleeding. If the clinical, laboratory, and instrumental data do not raise suspicion of sepsis in
necrotic collections, the FNAB should not be performed, owing to a potential risk of secondary
infection [73-76]. Surgical intervention is required in patients with fluid-necrotic septic
collection, also because the septic condition worsens the impairment of general condition and
organ failure On the other hand, not all patients with infected necrosis but without compromise
of general conditions and/or organ dysfunction will require urgent intervention [77,78]. This
therapeutic choice is based on the purpose to delay the surgical procedure for some weeks
when the collection has become walled off [79].
2.3. Choice of surgical approach for gatherings
All therapeutic choices in acute pancreatitis should be connected with the evolution of the
disease, which may be very complex. Organ failure (MODS) in the first phase of the disease is
usually not related to infection but to SIRS. However, septic complications of disorganized
necrotizing tissue can also occur in this phase, with further worsening of disease evolution [80].
The latter phase of the disease is characterized by a counteractive anti-inflammatory response
syndrome (CARS). In this phase there is the risk of infected necrosis and organ failure related
to infections. Gooszen et al. [81] report three scenarios in the late evolution of severe acute
pancreatitis. First is improvement with intensive care after early onset organ failure, but this
is followed by deterioration in the third or fourth week, often due to infection of necrosis.
Another scenario is clinical impairment without distinct early organ failure, most likely to be
caused by infected necrosis in the third or fourth week. In both cases further interventional
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procedures should be indicated. Finally, stable early onset organ failure without improvement
is also indicated in the second to third week; in this case the verification of collection infection
(FNAB, gas bubbles on CECT) can be useful for the programming of surgical intervention.
Sterile pancreatic peripancreatic fluid-necrotic collections require observation and conserva‐
tive treatment. This choice is based on the physiopathological evolution of necrotizing
pancreatitis. The principal characteristic that should be considered is the time of evolution of
necrotizing pancreatic gatherings: this period is usually very long, from 24-36 hours up to 12
weeks. This evolution goes through three phases until the resolution or constitution of acute
postnecrotic pseudocysts if the collection remains sterile [82]. In the first phase is true pancre‐
atic necrosis with minimal separation of devitalized tissues, with a high solid/liquid ratio. Then
comes the transitional pancreatic necrosis, also called the intermediate lesion. Infection can
arise in every occurrence of this phase. The following phase is organized pancreatic necrosis
with good separation of devitalized tissue within a fluid gathering, with development of a
fibrous-granular wall. This last phase can be defined as a walled-off pancreatic necrosis. The
acute postnecrotic pseudocyst is the final evolution characterized by the complete separation
of the tissues, with a liquid content and fibrous wall. Therefore, in most cases the sterile
asymptomatic pancreatic peripancreatic fluid-necrotic gatherings do not need treatment,
instead requiring only clinical-instrumental observation by US-CT every 4 to 6 weeks, because
the resolution can occur in 8 to 12 weeks in mean. There also exists in the literature extreme
data up to 280 days [83] or one year [84]. In the phase of walled-off pancreatic necrosis, infected
pancreatic peripancreatic necrotic fluid collections diagnosed by FNAB or gas bubbles on
CECT, or suspected infection but with the impairment of general condition, has traditionally
been considered an accepted indication for intervention. Based on the evolution of pancreatic
peripancreatic necrosis the importance of choice on the timing of intervention is evident. From
the data of the literature the almost unanimous conclusion is that the best choice is to delay
intervention until the fluid-necrotic collections are encapsulated, and thus called walled-off
necrosis. This process is usually completed in 4 to 6 weeks. If, during this evolution process of
pancreatic peripancreatic necrosis, the deterioration of general conditions occurs, the admin‐
istration of broad-spectrum antibiotics can prevent infections and it allows to delay of the
surgical procedure. Surgery in the first two weeks from the onset—frequently necrosectomy
for infected collections—has a mortality rate of 75% with a gradual decrease to 5% if performed
later than four weeks from the onset. Compromise of general condition and multiple organ
dysfunction causes a worsening of results [69,85-87]. In spite of the benefit of the postponing
intervention, it is not always possible to delay surgery if the general condition of patient
deteriorates, because infected collections can worsen organ failure in the first week of pan‐
creatitis [88]. In summary, the better results in the surgical treatment of fluid-necrotic pancre‐
atic gatherings are clearly connected to a suitable time interval—between the onset of
symptoms and intervention—for encapsulation of collection and the recovery of general
condition of the patient.
The surgical procedure employed in the treatment of pancreatic peripancreatic necrotic
gatherings in the last decade showed a progressive evolution to minimally invasive proce‐
dures. Nevertheless, in this setting there are no unanimously standardized and accepted
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surgical procedures, and so overall there are no clearly defined indications for various surgical
procedures. Until a short time ago, an open approach for infected necrotic collection (so called
open necrosectomy) was the standard, first choice, surgical procedure. In this open procedure,
the laparotomy is followed by complete debridement and necrosectomy and placement of a
retroperitoneal lavage system and drains in the lesser sac. The mortality rate of this procedure,
reported by Rau, is 25% [89]. Other open procedures are proposed but not commonly adopted,
and have uncertain result, such as closed packing with referred mortality 11% [90], and the
open abdomen strategy with planned relaparotomies, which has a very high mortality rate
(70%) [81]. These results should be considered in a very severe disease scenario.
Recently necrosectomy by a minimally invasive procedure, such as percutaneous minimally
invasive retroperitoneal necrosectomy, has been proposed [91]. Moreover the video-assisted
retroperitoneal debridement (VARD) [92,93], by the minimally invasive surgical approach,
aims to remove only some pieces of less adherent necrosis rather than all parts of the necrosis.
In this way we can reduce the risk of bleeding, and the remnant necrotic tissue can be resorbed.
This percutaneous procedure can be repeated, and drainage into cavity planned. Further
minimally invasive procedures for the treatment of infected pancreatic necrotic collection
include:
• Necrosectomy with minimally invasive step-up approach.
• Endoscopic transluminal necrosectomy (ETN).
• Percutaneous drainage.
The step-up approach has been proposed and compared with open necrosectomy in a Dutch
multicentre randomised study on acute necrotizing pancreatitis [94]. The comparison showed
minor complications with a step-up approach. This procedure consists of percutaneous or
transgastric drainage, and then drain-guided necrosectomy if necessary. This procedure,
which has been performed in some patients (35%), has achieved stable results only once.
In ETN the endoscopic access is usually transgastric. The procedure has a very low invasivity
but there is the need for repeated procedures to remove the necrotic collection [95].
2.4. The global evaluation of this minimally invasive procedure is in progress.
Finally we have to consider the simple, basic percutaneous drainage of septic necrotic
gatherings. The drainage is not necrosectomy but from the perspective of a minimally invasive
approach, with a real possibility that the necrotic tissue can be resorbed, the percutaneous
catheter drainage can be considered the first therapeutic approach in the case of (suspected or
documented) infected necrotic pancreatic gatherings. Percutaneous drainage has been largely
employed, but there is no complete therapeutic evaluation of this method. Recently many
results of systematic reviews have become available [87]: the technical success rate was 99%,
and the number of patients with necrotizing pancreatitis treated with percutaneous drainage
alone was high (22-55%). In summary, we can accept that after the first step (percutaneous
drainage) of a therapeutic programme for septic necrotic gatherings, if the drainage of the
collection is incomplete, it should be necessary to perform a complete necrosectomy. Finally
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we can conclude that it is not clear what the best procedure is for the treatment of septic necrotic
pancreatic collections. Open necrosectomy remains the last option after the failure of less
invasive procedures. A flow-chart of the management of pancreatic peripancreatic gatherings
is shown in figure 2.
Figure 2. Flow-chart: management of pancreatic-peripancreatic gatherings
Acute postnecrotic pseudocysts are the final evolution of necrotizing pancreatic gatherings,
characterized by complete separation of the tissues, with liquid content and a fibrous wall. The
incidence of acute pseudocysts is low, at 5-16% [82]. The evolution of a lesion with a fibrous
wall can be complete in many weeks (12-16 weeks). Small cysts (<5-6 cm) can be observed for
many months without clinical appearance. In some cases there is some spontaneous improve‐
ment until the resolution of the pseudocysts [96]. Treatment is required for a pseudocyst larger
than 6-7 cm, or one that is symptomatic or persistent over many months. There are various
surgical procedures for the treatment of pseudocysts. The pathological characteristic of acute
pseudocysts is the connection with pancreatic ducts. In fact simple percutaneous US/CT
guided drainage can be often followed by persistent leakage from the drain; other complica‐
tions of this procedure include infections and the repeated changes required of the drain [97].
Based on the communication of the pseudocysts with pancreatic ducts, all surgical procedures
should involve a cystodigestive prolonged connection (anastomosis, fistulas) for the steady
drainage of pancreatic secretions. During its development, the pseudocysts establish a
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connection with adjacent intestinal organs to which the cyst is adherent: usually the stomach,
small intestine, and duodenum. From this perspective there are various possible procedures.
Drainage of the pseudocyst by endoscopic techniques has been proposed [98,99]: this is
performed by creating a small opening between the cyst and stomach. The disadvantage of
this technique is incomplete drainage with recurrence of pseudocysts and infection because
the communication can be small and in site not declive. The surgical procedures use the
adjacent intestinal organ (stomach, duodenum, small intestine) involved in each case for
anastomosis with the cyst: cystogastrostomy, cystojejunostomy, cystoduodenostomy [96].
For cysts located in the body or tail of pancreas the cystojejunostomy or cystogastrostomy is
performed depending the development of the cyst above or under the mesocolon. For
pseudocysts developed in the head, cystoduodenostomy is usually performed. The same
surgical procedures can be performed with a laparoscopic approach with the advantage of the
minimal invasiveness.
3. Chronic pancreatitis
Chronic  pancreatitis  is  a  continuing,  progressive  inflammatory  process  of  the  pancreas,
characterized by irreversible changes in the morphology of the gland. The gradual fibrosis
of the parenchyma causes the loss of exocrine and endocrine functions. The incidence of
chronic  pancreatitis  ranges from 1.6  to  23 cases  per  100,000 population per  year  world‐
wide [100, 101]. The incidence and prevalence of chronic pancreatitis is low, and more than
50% are  alcohol  related.  The incidence of  the  disease  appeared to  be increasing in  past
decades  [102].  Whereas  in  acute  pancreatitis  tissue  alteration  may  be  reversible  in  the
oedematous form, chronic pancreatitis is characterized by irreversible tissue changes and
exocrine dysfunction. Chronic pancreatitis lies on a protracted inflammation of the pancreas
characterized by the permanent alteration of the basic anatomical structure accompanied
by functional deficits, even if the cause is eliminated. The cause of chronic disease is stable
tissue inflammation by various causes. Therefore, there are multiple hypotheses as to the
pathophysiology of chronic pancreatitis: necrosis-fibrosis, toxic-metabolic causes, plug and
stone formation,  duct  obstruction,  or  sentinel  acute  pancreatitis  event  (SAPE) [100].  The
pathological  features  are  pancreatic  parenchymal  fibrosis,  duct  dilation,  and  pancreatic
stones. Chronic abdominal pain characterizes the clinical appearance of the disease. Acute
and chronic diseases are connected based on pathological features: both are characterized
by a phlogistic process with autodigestive and/or ordinary varieties, interchangeable with
each other but with different development processes [103,104]. Inflammatory processes of
pancreatitis  are  generally  characterized  by  autodigestion,  but  less  frequently  ordinary,
uncharacteristic  interstitial  pancreatic  phlogosis  (as  reaction  to  general  disease)  without
signs of autodigestion can be observed. Both varieties of phlogosis can have an acute or
chronic course. The ordinary variety of pancreatitis can transgress to an autodigestive or a
chronic progressive variety at any time [105].
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3.1. Aetiological and nosographic assessment as a guide for surgery in the therapeutic
programmes
Chronic pancreatitis, in most cases caused by excessive alcohol consumption, is due to tissue
injury by persistent inflammation based ontoxic-metabolic hypothesis [106]. The pathologic
features are destruction of pancreatic parenchyma, substitution with large fibrosis, and
infiltration of inflammatory cells in various degrees [107].
Generally the effect of alcohol is amplified by a high fat diet and smoking [108]. Smoking can
be an independent risk factor for the development and progression of chronic pancreatitis.
Smoking can have adverse effects on the secretion of pancreatic bicarbonate and water and
causespancreatic calcifications through oxidative stress.. Other less common causes of chronic
pancreatitis include autoimmune-immunologic causes in autoimmune diseases such as
primary autoimmune pancreatitis or associated with Crohn’s disease; genetic/hereditary
pancreatitis with autosomal dominant or recessive mutations in the cationic trypsinogen gene
(PRSSI-SPINK1); severe hypercalcaemia with protein plug obstructive hypothesis; obstructive
chronic pancreatitis (pancreatic adenocarcinoma, neuroendocrine tumours, intrapapillary
mucinous tumours, annular pancreas, pancreas divisum, etc.); nutritional factor deficiencies;
and idiopathic causes (table 8).
Common causes Less common causes
Alcohol
Tobacco smoking
Severe hypercalcaemia
Autoimmune
Genetic
Duct obstruction
Hyperlipidaemia
Idiopathic
Table 8. Aetiology of chronic pancreatitis
Recurrent episodes of heavy abdominal pain with back bilateral diffusion, but without
compromise of general condition, and a history of abnormal alcohol consumption for many
years, characterized the clinical appearance of ten patients with chronic pancreatitis. Our
patients were subdivided into stage A and B of Amman’s classification [109]: six patients in
Stage A, initial, characterized by recurrent acute attacks, with mild impairment of pancreatic
function; and four patients in Stage B, later, with increasing abdominal pain and more frequent
acute attacks, with some complications such as chronic pseudocysts and main pancreatic duct
dilation, and impaired pancreatic function. In end-stage disease (none of our patients were in
this stage) there are decreases in acute attacks and abdominal pain intensity, and marked
impairment of pancreatic function. The diagnosis of chronic pancreatitis is simple in the later
stages, but difficult in the initial stages. Laboratory and instrumental (EUS, CT) examinations
have confirmed the diagnosis following a EUS-based criterion. The new Rosemont classifica‐
tion [110] of chronic pancreatitis identifies major criteria such as main pancreatic duct calculi
and lobularity with honeycombing and hyperechoic foci with shadowing. Minor criteria were
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cysts, dilated ducts >3.5 mm, irregular pancreatic duct contour, dilated side branches >1 mm,
hyperechoic duct wall, and non-shadowing hyperechoic foci.
In our experience the diagnosis was based on imaging exams with confirmation of the main
pancreatic duct and branch ducts being irregularity dilated or having stenosis and calcifica‐
tions in some ducts. The common pancreatic function tests (focal elastase, fasting blood
glucose/oral glucose tolerance tests) do not detect mild or moderate exocrine pancreatic
insufficiency. Therefore these tests are subsidiary in the current clinical evaluation of chronic
pancreatitis. In chronic pancreatitis the indication of the surgical approach comes after a long
clinical evolution of the disease with a well-established diagnosis. In our experience chronic
pancreatitis has been treated through an operative therapeutic approach in four patients: direct
ductal-enteric drainage (Puestow procedure) in two patients; longitudinal pancreaticojeju‐
nostomy combined with a local pancreatic head resection (Frey procedure) in one patient; and
pancreatoduodenectomy (Whipple procedure) in one patient. The remaining six patients have
undergone conservative treatment that involves control and management of steatorrhoea,
malnutrition and pain.
3.2. Role of surgery in the treatment of chronic pancreatitis
The pathological patterns of chronic pancreatitis are focused on inflammation and fibrosis of
pancreatic parenchyma, stricture, and obstruction of the main and accessory ducts and
intraductal calcification [111,112]. The particular histopathological characteristics are areas of
acute inflammation and foci of pancreatic cell necrosis. The pain is connected with the foci of
parenchymal inflammation and ductal hypertension. Also, the inflammatory damage of the
sensory nerves of the pancreas can play a role in the development of the symptoms in chronic
pancreatitis [113]. The first question concerns the indications for surgery in chronic pancrea‐
titis: the principal symptom of chronic pancreatitis is abdominal pain. The most severe
intractable pain is the cornerstone of surgical indication. The surgical treatment of chronic
pancreatitis should be based on the clinical and pathological scenario: two types of surgical
procedures are proposable. Decompression procedures with the aim of improving or elimi‐
nating ductal hypertension by intestinal anastomotic drainage can be performed. Resectional
procedures aim to eliminate areas of chronic inflammation that are especially present in the
head of the pancreas. There are also denervation procedures involving neurolysis of the celiac
trunk and ganglia; the data from the literature report variable results [114]. The decompression
procedure can involve the endoscopic treatment [115]. In the course of chronic pancreatitis,
evident ductal dilation can develop as a late complication. The incidence of these chronic
pseudocysts is high: 20-40% [85]. The endoscopic procedure aims to perform cystogastrostomy
or duodenocystostomy following the development and anatomical connection between the
pseudocyst and intestinal organ (stomach or duodenum) [116]. The morbidity of this proce‐
dure ranges from 3-11% with no mortality. The endoscopic approach can allow the treatment
of the chronic pseudocyst by drainage through the duodenal papilla and ductal system. The
procedure develops with selective endoscopic pancreatic sphincterotomy retrograde pancrea‐
tography and the positioning of the transpapillary endoprotesis as drainage. The morbidity
ranges from 2-7% with no mortality [116]. If intraductal stones are present, this approach can
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allow transluminal stone removal and/or lithotripsy, followed by prolonged pancreatic duct
stenting [115-117]. Unfortunately the endoscopic approaches are not always feasible because
the anatomic difficulties such as location of the cysts, papillary patency, etc. The surgical
management of pancreatic duct stones and stenosis has shown better results than endoscopic
treatment [118,119]. The Puestow procedure [120] and its modification of Partington and
Rochelle [121] are the standard surgical drainage methods in chronic pancreatitis with dilated
ducts. In the original presentation there is the resection of the tail of pancreas, longitudinal
incision of the main dilated duct along the body of the pancreas, and invaginating anastomosis
with a Roux-en-Y loop of jejunum. The following modification is the elimination of the
resection of the pancreatic tail. The immediate results of the procedure show very low mortality
(less than 1%) and morbidity (less than 10%) [122]. Pain is relieved in 85-90% of patients;
recurrent pain is observed in 30% [123-125].
In some patients with a dilated pancreatic duct, a fibrotic, inflammatory mass may be present
in the head of the pancreas. In these patients, surgical approaches that couple drainage and
resective procedures can be indicated. These interventions can be defined as ‘hybrid’ [125] and
show numerous variants. In duodenum-preserving pancreatic head resection (DPPHR)
proposed by Beger [126], the neck of the pancreas is divided, most of the head is resected
sparing the CBD and duodenum, and the procedure is completed by side-to-side pancreato‐
jejunostomy (Roux-en-Y). Berne modification of DPPHR consists of excavation of the head of
the pancreas, without division of the pancreatic neck, completed by pancreaticojejunostomy
(Roux-en-Y) [127]. Frey described the local resection of the head of the pancreas and longitu‐
dinal pancreatico-jejunostomy (LR-LPJ) [128]. Subsequently local resection of the pancreatic
head with longitudinal pancreaticojejunostomy (Roux-en-Y) by Frey Hamburg modification
[129], with the inclusion of the excavation of the central portion of uncinate process, in
continuity with the V-shaped excavation of the body along the main pancreatic duct, has been
proposed. All these hybrid surgical procedures give results that overlap, with a very low
mortality (less than 1%) and a rate of morbidity from 20-30% [125]. Pain relief occurs in 80-85%
of patients, also in late control [130].
The resective procedures had a general indication for the prevalence of the chronic phlogistic
process in the pancreas parenchyma with lesser duct dilations. Pancreatoduodenectomy,
generally called the Whipple procedure, is effective in managing pain in 70-90% of patients.
The mortality is less than 5% but the morbidity can reach 40% [131]. Similar results are obtained
with pylorus-preserving pancreatoduodenectomy (PPPD). The major problem of these
surgical resective procedures is the pancreatic anastomotic leak that can occur with a variable
incidence range from 10-30% or more. Although the pancreatic parenchyma in chronic disease
generally has a hard consistency, the size of the main duct in the gland with diffuse sclerosis
can be very small, at around 2-3 mm, and consequently difficult for anastomosis. Other
resectional procedures are also proposed. Distal pancreatectomy, for example, has been
proposed for the patients in whom the fibrotic process of the pancreas is located in the body
and tail. These procedures have had medium results, resulting in pain relief in 60% of patients
[132]. Almost total distal pancreatectomyand total pancreatectomy achieve good relief of
abdominal pain but the metabolic consequences are an adverse result [133]. Pancreatectomy
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with islet auto-transplantation has been proposed [134] with interesting results but its use is
limited by diffusion. A flow-chart of therapeutic management in chronic pancreatitis is shown
in figure 3.
Figure 3. Flow-chart: management of chronic pancreatitis
4. Conclusions
The management of severe acute pancreatitis requires a radical revision. The role of the surgery
should be limited to percutaneous drainage of septic-necrotic collections, a procedure that in
most cases could reduce the need for surgical intervention. If major surgical interventions are
required, these should be as conservative as possible, and minimally invasive approaches are
preferred [135].
In summary, chronic pancreatitis with duct obstruction, stones and protein plugs, chronic
pseudocysts and abdominal pain exacerbation may be treated with drainage operations. Major
resection procedures have infrequent indications based on prevalent phlogistic involvement
of pancreatic parenchyma, non-dilated pancreatic ducts, and enlarged pancreatic head.
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In conclusion, based on pathological and clinical observations, we can believe that the surgical
interventions that couple the drainage of the distal pancreas and resection of the core of the
head are procedures with acceptable results in the treatment of chronic pancreatitis.
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